Drugs.com Clinical Trial ResultsOriginal article
MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa
Phase 3SonelokimabNeutral
AI Analysis
Summary
MoonLake Immunotherapeutics announced Week 52 results from its Phase 3 VELA program evaluating Sonelokimab in hidradenitis suppurativa. The announcement provides interim efficacy and safety data from the ongoing trial.
Clinical Trial Data
Phase
Phase 3
Outcome Details
Week 52 results announced
Importance:6/10
Sentiment:
0.00
Phase 3Data ReadoutHidradenitis SuppurativaVELA Program
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on June 21, 2026 11:07 PM